HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize
by HHS and Steven & Alexandra Cohen Foundation
USPTO issues HelixBind patent US 11,840,721 covering
improved methods for detecting microbial infections.
HelixBind announces the award of $6 million of non-dilutive funding in 2023
to advance the company's RaPID diagnostic platform.
USPTO issues HelixBind patent US 11,713,330 covering methods for ultrasensitive direct detection
of microorganisms, including Borrelia, the causative pathogen of Lyme Disease.
USPTO issues HelixBind patent US 11,590,507 covering reagent carriers for fluidic systems.
HelixBind announces $9 million in non-dilutive financing from the NIH in 2022 to support the
development of assays for the direct detection and identification of infections.
HelixBind selected as Phase 1 winner of the LymeX Diagnostics Prize competition from
the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation.
USPTO issues HelixBind patent US 11,414,712 covering methods to identify microbial species
direct from complex specimens, such as blood.
Japanese Patent Office (JPO) issues HelixBind patent JP 7073328 covering multiple aspects
of HelixBind’s sample-to-answer automated device.
Japanese Patent Office (JPO) issues HelixBind patent JP 7046603 covering the company’s method
for the identification of microbial infections directly from human specimens.
The China National Intellectual Property Administration (CNIPA) issues HelixBind
patent number CN 109414695 covering certain aspects of its integrated fluidic devices.
USPTO issues HelixBind patent US 11,091,814 covering the methods
to detect bacterial and/or fungal genomic material in a sample.